Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial
- 1 May 2024
- journal article
- research article
- Published by Wiley in Helicobacter
- Vol. 29 (3) , e13098
Abstract
Background: Potassium‐competitive acid blockers have demonstrated enormous potential in the eradication treatment of Helicobacter pylori infection, with tegoprazan being one of the representatives. The available data on the safety and efficacy of tegoprazan in dual therapy are limited.Materials and Methods: The multicenter, noninferiority, randomized‐controlled trial was conducted from May 2023 to March 2024. Treatment‐naive subjects were randomly assigned (1:1) to enter either the tegoprazan–amoxicillin (TA) group (tegoprazan 50 mg twice daily and amoxicillin 750 mg four times daily) or the esomeprazole–amoxicillin (EA) group (esomeprazole 20 mg and amoxicillin 750 mg all four times daily), with a duration for 14 days. The primary outcome was eradication rate as determined by 13C‐urea breath test, including per‐protocol (PP) analysis and intention‐to‐treat (ITT) analysis. Secondary outcomes were adverse events and compliance.Results: A total of 368 individuals were included in the randomization. The eradication rates in the EA group and the TA group were 84.2% and 85.8%, respectively, according to an ITT analysis (p = 0.77), and 88.5% and 88.2%, respectively, according to PP analysis (p = 1.00). The eradication rates for the TA group were not inferior to those of the EA group in both PP (p = 0.0023) and ITT analyses (p = 0.0009). There were no significant statistical differences in the incidence of adverse events and compliance between the two groups. The multivariate logistic regression analysis revealed that poor compliance increased the risk of eradication failure (p < 0.001).Conclusions: Dual therapy containing tegoprazan is safe and effective to be considered as a clinical first‐line treatment option, but further optimization involving antimicrobial susceptibility testing and adjustments in dosage and frequency is warranted.Trial Registration: ClinicalTrials.gov ID: NCT05870683.Keywords
Funding Information
- Key Technology Research and Development Program of Shandong Province
- National Natural Science Foundation of China
This publication has 22 references indexed in Scilit:
- Vonoprazan: A Review in Helicobacter pylori InfectionDrugs, 2024
- Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysisThe Lancet Gastroenterology & Hepatology, 2023
- Evolving Concepts in Helicobacter pylori ManagementGastroenterology, 2023
- Helicobacter pylori infectionNature Reviews Disease Primers, 2023
- Global burden of gastric cancer: epidemiological trends, risk factors, screening and preventionNature Reviews Clinical Oncology, 2023
- Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or EsomeprazoleClinical Pharmacokinetics, 2023
- Dual therapy for Helicobacter pylori infectionChinese Medical Journal, 2023
- 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatmentChinese Medical Journal, 2022
- The current role of dual therapy for treatment of Helicobacter pylori: back to the future?European Journal of Gastroenterology & Hepatology, 2020
- Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ‐12420), a novel potassium‐competitive acid blocker, in healthy male subjectsAlimentary Pharmacology & Therapeutics, 2019